Acupath Laboratories, Inc.

03/24/2025

Lumea, AIRA Matrix, and Acupath have Partnered to Provide a Diagnostic AI Solution for the URO17® Bladder Cancer Biomarker

LEHI, UT, UNITED STATES, March 20, 2025 /EINPresswire.com/ — Lumea, a leader in digital pathology solutions. AIRA Matrix Private Limited, an innovative technology company for AI-based diagnostic, prognostic, and predictive applications in cancer care. Acupath, a leading provider of sub-specialized anatomic and molecular pathology services. These companies have joined forces to deliver an AI-based solution to assist in the diagnosis of urinary bladder cancers through cytopathological examination.

Read more:

Lumea, AIRA Matrix, and Acupath have partnered to provide a Diagnostic AI Solution for the URO17® Bladder Cancer Biomarker. Read more...

01/07/2025

The American Cancer Society's estimates for cervical cancer in the United States for 2024 were:

About 13,820 new cases of invasive cervical cancer will be diagnosed.

About 4,360 women will die from cervical cancer.
Cervical pre-cancers are diagnosed far more often than invasive cervical cancer.

Cervical cancer is most frequently diagnosed in women between the ages of 35 and 44, with the average age being 50. It rarely develops in women younger than 20.

Many older women don't realize that they are still at risk of developing cervical cancer as they age. More than 20% of cervical cancers are found in women over 65. However, these cancers rarely occur in women who have been getting regular tests to screen for cervical cancer before they were 65.

As always, screening is a key to diagnose any cancer, especially cervical, in the beginning stages.

For more information: https://www.cancer.org/cancer/types/cervical-cancer/about/key-statistics.html

12/20/2024

The Annual Acupath Ugly Sweater Contest 2024...and they did not disappoint!!! Thank you to our staff for your participation and for always being team players! Happy Holidays!
Congratulations to Jenny for winning the coveted "Ugly Sweater 2024"!

09/10/2024

Acupath celebrates those brave warriors that are battling, fighting, and winning against Childhood Cancer, Leukemia, Lymphoma, Uterine Cancer, Ovarian Cancer, Prostate Cancer and Thyroid Cancer.

May they continue making strides and beating the odds!

08/21/2024

In observance of the Labor Day holiday, kindly review our schedule to plan for your specimens accordingly.

08/05/2024

August is National Summer Sun Safety Month!

Skin Cancer is the MOST common of all cancer types.
According to the American Cancer Society®, more than 5 million skin cancers are diagnosed and treated each year in the United States. That’s more than all other cancer’s combined. With the diagnosis rate increasing over the past few decades, proper prevention is key.

07/18/2024

How common is Bone Cancer?

Bone cancer, while rare, can be quite serious. Acupath Laboratories, Inc. would like to share some key points based on information that is available:

Statistics and Types of Bone Cancer
Early Detection and Symptoms
Diagnosis and Pathology

To read the article in it's entirety: https://lnkd.in/esuS4K7J

For more information about Acupath Laboratories Orthopedic Pathology, email us at info@acupath.com or 1-888-ACUPATH (228-7284)

05/06/2024

May is Bladder Cancer Awareness month!

Acupath highlights that while urine cytology, urinalysis, and AcuURO-17 are all diagnostic tests that involve urine, they are quite different.

Urinalysis and urine cytology indeed play crucial roles and are essential diagnostic tools in the field of urology and contribute significantly to the early detection and management of urinary tract disorders, AcuURO-17 is a diagnostic tool designed to enhance the detection of urothelial carcinoma. Unlike traditional urine cytology, which may struggle to accurately identify low-grade carcinoma, the AcuURO-17 offers improved sensitivity and specificity for detecting both high-grade and low-grade urothelial carcinoma.

This diagnostic test utilizes a panel of biomarkers or molecular signatures present in urine samples associated with urothelial carcinoma. By analyzing these specific markers, the AcuURO-17 can provide a more comprehensive assessment of the presence and severity of urothelial carcinoma compared to conventional urine cytology.

To read the full article, visit our website: www.acupath.com/news/

For more information about our AcuURO-17, email us at uro17@acupath.com

04/22/2024

During Lab Week 2024, the Red Team performed a custom song written by Michelle Huggard, as she strummed her guitar! Great Job!

During Lab Week 2024, our Red Team performed a custom song, written by Michelle Huggard, as she strummed her guitar! Great Job!